The management of infectious disease is challenged by trends that impact patient welfare on a global scale; the emergence of multi-drug-resistant (MDR) forms of new and old bacterial pathogens, the world’s increasing population of immunocompromised patients where antimicrobial therapy is less effective, and fewer new antibiotics being licensed. If these trends continue, the dreaded “post-antibiotic era” could become a reality. Fraser Leslie of Arsanis discusses the vast potential of monoclonals for combating antibiotic resistance with many anti-infectious mAbs currently in development.
https://international-pharma.com/wp-content/uploads/2014/12/Opportunities.pdf